Vanguard Global Advisers
COGT icon

Vanguard Global Advisers’s Cogent Biosciences COGT Stock Holding History

Vanguard Global Advisers’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Buy
79,111
+9,514
+14% +$333K ﹤0.01% 1002
2026
Q1 		$2.68M Buy
+69,597
New +$2.57M ﹤0.01% 1014

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Global Advisers's COGT Position: Q2 2026 in Review

Vanguard Global Advisers increased its Cogent Biosciences (COGT) stake by 14% in Q2 2026, buying an estimated $333K and bringing the position to 79,111 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

Vanguard Global Advisers first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Vanguard Global Advisers held 79,111 shares of Cogent Biosciences worth $3.06M as of Q2 2026.
  • Vanguard Global Advisers bought 9,514 Cogent Biosciences shares in Q2 2026, an estimated $333K.
  • Cogent Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1002 holding.
  • Vanguard Global Advisers first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 318 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.